Cardioprotective effects of deferoxamine in acute and subacute cardiotoxicities of doxorubicin: a randomized clinical trial

The Egyptian Heart Journal

Table 1 Demographic and disease characteristics of the study patients

Parameters	Group 1 (n = 20)	Group 2 (n = 20)	Group 3 (n = 20)	P_1,2	P_1,3	P_2,3	ANOVA
Age (year)	6.85 ± 4.92	8.17 ± 4.76	8.69 ± 4.89	0.40	0.27	0.75	0.50
Body surface area (m²)	0.94 ± 0.41	0.94 ± 0.34	1.05 ± 0.33	0.96	0.40	0.38	0.63
Treatment duration (month)	8.70 ± 2.20 (6–15)	7.49 ± 1.43 (6–11)	7.81 ± 1.42 (6–11)	0.22	0.17	0.79	0.25
Doxorubicin dosage (mg)	189.20 ± 127.5	232.50 ± 99.16	204 ± 108.6	0.25	0.70	0.44	0.49

Group 1: control group; group 2: intervention with deferoxamine 10-times the doxorubicin dose; group 3: intervention with deferoxamine 50 mg/kg